<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Losartan</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Losartan">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Losartan</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Losartan</b>, sold under the trade name <b>Cozaar</b> among others, is a medication mainly used to treat high blood pressure.<span class="mw-ref" id="cite_ref-AHFS2017_2-0"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is also used for diabetic kidney disease, heart failure, and left ventricular enlargement.<span class="mw-ref" id="cite_ref-AHFS2017_2-1"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is taken by mouth.<span class="mw-ref" id="cite_ref-AHFS2017_2-2"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It may be used alone or in addition to other blood pressure medication.<span class="mw-ref" id="cite_ref-AHFS2017_2-3"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Up to six weeks may be required for the full effects to occur.<span class="mw-ref" id="cite_ref-AHFS2017_2-4"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


<p></p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Losartan</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Losartan_structure.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Losartan_structure.svg.png" data-file-width="662" data-file-height="488" data-file-type="drawing" height="147" width="200"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Losartan-3D-spacefill.png" tppabs="https://ptable.com/wiki/compounds/I/m/Losartan-3D-spacefill.png" data-file-width="2000" data-file-height="1454" data-file-type="bitmap" height="145" width="200"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pronunciation</th><td><span class="rt-commentedText nowrap"><span class="IPA nopopups noexcerpt">/<span style="border-bottom:1px dotted"><span>l</span><span>oʊ</span><span>ˈ</span><span>s</span><span>ɑːr</span><span>t</span><span>ən</span></span>/</span></span><span> </span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Cozaar, others</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/losartan-potassium.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/losartan-potassium.html'" tppabs="https://www.drugs.com/monograph/losartan-potassium.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a695008.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a695008.html'" tppabs="https://medlineplus.gov/druginfo/meds/a695008.html" class="external text external">a695008</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Losartan  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Losartan'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Losartan" class="external text external">Losartan</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Losartan&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Losartan&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Losartan&SearchType=BasicSearch" class="external text external">Losartan</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>D<span> </span><span class="mw-ref" id="cite_ref-Pregnancy_1-0"><a href="#cite_note-Pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>D (Evidence of risk)<span> </span><span class="mw-ref" id="cite_ref-Pregnancy_1-1"><a href="#cite_note-Pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Drug class</th><td>Angiotensin II receptor antagonist</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>C09CA01<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=C09CA01  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=C09CA01'" tppabs="https://www.whocc.no/atc_ddd_index/?code=C09CA01" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li>
<li>In<span>&nbsp;</span>general: ℞<span>&nbsp;</span>(Prescription only)</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>25–35%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>99.7% (primarily albumin)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Liver (CYP2C9, CYP3A4)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>1.5–2 hours</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Kidney 13–25%, biliary 50–60%</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">(2-butyl-4-chloro-1-{[2'-(2<i>H</i>-tetrazol-5-yl)biphenyl-4-yl]methyl}-1<i>H</i>-imidazol-5-yl)methanol</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=114798-26-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=114798-26-4'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=114798-26-4" class="external text external">114798-26-4</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/3961  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/3961'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/3961" class="external text external">3961</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=590  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=590'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=590" class="external text external">590</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00678  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00678'" tppabs="https://www.drugbank.ca/drugs/DB00678" class="external text external">DB00678</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.3824.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.3824.html'" tppabs="http://www.chemspider.com/Chemical-Structure.3824.html" class="external text external">3824</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=JMS50MPO89  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=JMS50MPO89'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=JMS50MPO89" class="external text external">JMS50MPO89</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D08146  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D08146'" tppabs="https://www.kegg.jp/entry/D08146" class="external text external">D08146</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6541  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6541'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6541" class="external text external">CHEBI:6541</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL191  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL191'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL191" class="external text external">ChEMBL191</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID7023227  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID7023227'" tppabs="https://comptox.epa.gov/dashboard/DTXSID7023227" class="external text external">DTXSID7023227</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.110.555  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.110.555'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.110.555" class="external text external">100.110.555</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>22</sub><span>H</span><sub>23</sub><span>Cl</span><span>N</span><sub>6</sub><span>O</span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">422.92</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC%28O%29%5BC%40H%5D%28C%28C%29C%29N%28Cc1ccc%28cc1%29c1ccccc1c1n%5BNH%5Dnn1%29C%28%3DO%29CCCC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC%28O%29%5BC%40H%5D%28C%28C%29C%29N%28Cc1ccc%28cc1%29c1ccccc1c1n%5BNH%5Dnn1%29C%28%3DO%29CCCC'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC%28O%29%5BC%40H%5D%28C%28C%29C%29N%28Cc1ccc%28cc1%29c1ccccc1c1n%5BNH%5Dnn1%29C%28%3DO%29CCCC" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">O=C(O)[C@H](C(C)C)N(Cc1ccc(cc1)c1ccccc1c1n[NH]nn1)C(=O)CCCC</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:PSIFNNKUMBGKDQ-UHFFFAOYSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458612349&page2=Losartan  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458612349&page2=Losartan'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458612349&page2=Losartan" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>Common adverse effects include muscle cramps, stuffy nose, cough, high blood potassium and anemia.<span class="mw-ref" id="cite_ref-AHFS2017_2-5"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Severe adverse effects may include angioedema, low blood pressure, and kidney problems.<span class="mw-ref" id="cite_ref-AHFS2017_2-6"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Use during pregnancy may result in harm to the baby.<span class="mw-ref" id="cite_ref-AHFS2017_2-7"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-Pregnancy_1-2"><a href="#cite_note-Pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Use is not recommended during breastfeeding.<span class="mw-ref" id="cite_ref-Pregnancy_1-3"><a href="#cite_note-Pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> It is in the angiotensin receptor blocker family of medication. It works by blocking angiotensin II.<span class="mw-ref" id="cite_ref-AHFS2017_2-8"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


<p>Losartan was patented in 1986, and approved for medical use in the United States in 1995.<span class="mw-ref" id="cite_ref-AHFS2017_2-9"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-Fis2006_3-0"><a href="#cite_note-Fis2006-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> It is on the World Health Organization's List of Essential Medicines.<span class="mw-ref" id="cite_ref-WHO21st_4-0"><a href="#cite_note-WHO21st-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> It is available as a generic medication.<span class="mw-ref" id="cite_ref-BNF69_5-0"><a href="#cite_note-BNF69-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span>  In 2017, it was the ninth most commonly prescribed medication in the United States, with more than 51 million prescriptions.<span class="mw-ref" id="cite_ref-Top300Drugs_6-0"><a href="#cite_note-Top300Drugs-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> A version combined with <a href="Hydrochlorothiazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydrochlorothiazide" title="Hydrochlorothiazide">hydrochlorothiazide</a> is available<span class="mw-ref" id="cite_ref-AHFS2017_2-10"><a href="#cite_note-AHFS2017-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> and, in 2017, it was the 67th most commonly prescribed medication in the United States, with more than eleven million prescriptions.<span class="mw-ref" id="cite_ref-Top300Drugs_6-1"><a href="#cite_note-Top300Drugs-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-8"><a href="#cite_note-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    

<p>Losartan is used for hypertension, including in people with left ventricular hypertrophy (enlarged heart muscle), and kidney dysfunction among type II diabetics.<span class="mw-ref" id="cite_ref-Cozaar_FDA_label_9-0"><a href="#cite_note-Cozaar_FDA_label-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> It may also delay progression of diabetic nephropathy. It is a suitable pharmacological agent for the reduction of renal disease progression in patients with type 2 diabetes, hypertension, and microalbuminuria (&gt;30<span>&nbsp;</span>mg/24 hours) or proteinuria (&gt;900<span>&nbsp;</span>mg/24 hours).<span class="mw-ref" id="cite_ref-pmid16761901_10-0"><a href="#cite_note-pmid16761901-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>

<p>Although evidence shows calcium channel blockers and thiazide-type diuretics are preferred first-line treatments for most people (due to both efficacy and cost), an angiotensin II receptor antagonist such as losartan is recommended as first-line treatment in people under the age of 55 who cannot tolerate an ACE inhibitor.<span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> One study demonstrated losartan was superior to <a href="Atenolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Atenolol" title="Atenolol">atenolol</a> in the primary prevention of adverse cardiovascular events (myocardial infarction or stroke), with a reduction in cardiovascular morbidity and mortality for a comparable reduction in blood pressure. The maximal effects on blood pressure usually occur within 3–6 weeks of starting losartan.<span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    
<p>The most common adverse effects for losartan in adults are upper respiratory infections, dizziness, and back pain.<span class="mw-ref" id="cite_ref-Cozaar_FDA_label_9-1"><a href="#cite_note-Cozaar_FDA_label-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> People with type 2 diabetes and kidney disease may experience diarrhea, fatigue, low blood pressure, low blood glucose, elevated potassium, chest pain, or allergic reaction.<span class="mw-ref" id="cite_ref-Cozaar_FDA_label_9-2"><a href="#cite_note-Cozaar_FDA_label-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> Losartan should not be taken by people who are diabetic and taking <a href="Aliskiren.htm" tppabs="https://ptable.com/wiki/compounds/A/Aliskiren" title="Aliskiren">aliskiren</a>.<span class="mw-ref" id="cite_ref-Cozaar_FDA_label_9-3"><a href="#cite_note-Cozaar_FDA_label-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> Anemia may occur, due to inhibition of the renin–angiotensin system.<span class="mw-ref" id="cite_ref-Cheungpasitporn2015_13-0"><a href="#cite_note-Cheungpasitporn2015-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> As with other angiotensin receptor blockers, losartan may injure the liver, although this effect appears to be rare.<span class="mw-ref" id="cite_ref-14"><a href="#cite_note-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> Electrolyte imbalances may occur in people taking losartan with kidney problems.<span class="mw-ref" id="cite_ref-Cozaar_FDA_label_9-4"><a href="#cite_note-Cozaar_FDA_label-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> Adverse outcomes do not differ by sex, age or race.<span class="mw-ref" id="cite_ref-Cozaar_FDA_label_9-5"><a href="#cite_note-Cozaar_FDA_label-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pregnancy">Pregnancy</h3></summary>
    
<p>In October 2014, the U.S. Food and Drug Administration (FDA) issued a black box warning that losartan can cause fetal toxicity, and should be discontinued as soon as pregnancy is detected.<span class="mw-ref" id="cite_ref-fda_15-0"><a href="#cite_note-fda-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-Cozaar_FDA_label_9-6"><a href="#cite_note-Cozaar_FDA_label-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> Using losartan while pregnant could result in fetal injury or death.<span class="mw-ref" id="cite_ref-fda_15-1"><a href="#cite_note-fda-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-Cozaar_FDA_label_9-7"><a href="#cite_note-Cozaar_FDA_label-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Overdose">Overdose</h3></summary>
    

<p>Overdosing would most likely result in decreased blood pressure, which could manifest as an increased heart rate, dizziness, feeling light headed, or loss of consciousness. Mice studies showed that lethality occurred at about 44 to 170 times the maximum recommended dose after the mice weight were adjusted.<span class="mw-ref" id="cite_ref-Cozaar_FDA_label_9-8"><a href="#cite_note-Cozaar_FDA_label-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Interactions">Interactions</h3></summary>
    
<p>Losartan may have adverse interactions with <a href="Phenobarbital.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenobarbital" title="Phenobarbital">phenobarbital</a>, <a href="Rifampicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Rifampin" title="Rifampin" class="mw-redirect">rifampin</a>, or <a href="Fluconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluconazole" title="Fluconazole">fluconazole</a>, possibly inhibiting its blood pressure-lowering effects.<span class="mw-ref" id="cite_ref-Cozaar_FDA_label_9-9"><a href="#cite_note-Cozaar_FDA_label-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Contamination">Contamination</h3></summary>
    
<div role="note" class="hatnote navigation-not-searchable">See also: <a href="Valsartan.htm#recalls" tppabs="https://ptable.com/wiki/compounds/A/Valsartan#recalls" title="Valsartan">Valsartan §<span>&nbsp;</span>recalls</a>, and Angiotensin II receptor blocker §<span>&nbsp;</span>recalls</div>

<p>Between November 2018, and September 2019, the FDA announced multiple recalls of tablets containing losartan by Sandoz, Torrent Pharmaceuticals, Hetero Labs, Camber Pharmaceuticals, Legacy Pharmaceutical Packaging, Teva Pharmaceuticals, Vivimed Life Sciences, and Macleods Pharmaceutical Limited due to detection of one of the possible carcinogens N-nitrosodiethylamine, N-methylnitrosobutyric acid, or N-nitroso-N-methyl-4-aminobutyric acid in the active pharmaceutical ingredient (API).<span class="mw-ref" id="cite_ref-16"><a href="#cite_note-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span><span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span><span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span><span class="mw-ref" id="cite_ref-19"><a href="#cite_note-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span><span class="mw-ref" id="cite_ref-20"><a href="#cite_note-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span><span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span><span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span><span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span><span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span><span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span><span class="mw-ref" id="cite_ref-28"><a href="#cite_note-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span><span class="mw-ref" id="cite_ref-29"><a href="#cite_note-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span><span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span><span class="mw-ref" id="cite_ref-31"><a href="#cite_note-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span><span class="mw-ref" id="cite_ref-32"><a href="#cite_note-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span><span class="mw-ref" id="cite_ref-33"><a href="#cite_note-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism_of_action">Mechanism of action</h2></summary>
    
<div class="thumb tleft"><div class="thumbinner" style="width:614px"><img src="../I/m/Renin-angiotensin-aldosterone_system.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Renin-angiotensin-aldosterone_system.svg.png" data-file-width="1050" data-file-height="585" data-file-type="drawing" height="341" width="612"><div class="thumbcaption" style="text-align: left">Renin-angiotensin-aldosterone system (RAAS)</div></div></div>
<p>Losartan is a selective, competitive angiotensin II receptor type 1 (AT<sub>1</sub>) antagonist, reducing the end organ responses to angiotensin II. Losartan administration results in a decrease in total peripheral resistance (afterload) and cardiac venous return (preload). All of the physiological effects of angiotensin II, including release of <a href="Aldosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Aldosterone" title="Aldosterone">aldosterone</a>, are antagonized in the presence of losartan. Reduction in blood pressure occurs independently of the status of the renin–angiotensin system. As a result of losartan dosing, plasma renin activity increases due to removal of the angiotensin II feedback. Renin is released from the kidneys when there is reduced renal arterial pressure, sympathetic activation, or increased sodium delivery to the distal renal tubule.<span class="mw-ref" id="cite_ref-:1_34-0"><a href="#cite_note-:1-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span> Renin then acts by converting angiotensinogen to angiotensin I; angiotensin converting enzyme (ACE) converts angiotensin I to angiotensin II; angiotensin II causes vasoconstriction and aldosterone release.<span class="mw-ref" id="cite_ref-:1_34-1"><a href="#cite_note-:1-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span> Aldosterone serves to retain sodium from the distal renal tubule. Sodium retention ultimately results in increased blood pressure.<span class="mw-ref" id="cite_ref-35"><a href="#cite_note-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span> Therefore, the use of angiotensin II receptor antagonists like losartan result in blocking the downstream effect of renin, angiotensin II, and ultimately decreasing blood pressure.</p>

<p>Angiotensin II receptor antagonists include losartan, <a href="Valsartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Valsartan" title="Valsartan">valsartan</a>, azilsartan, <a href="Candesartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Candesartan" title="Candesartan">candesartan</a>, <a href="Eprosartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Eprosartan" title="Eprosartan">eprosartan</a>, <a href="Irbesartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Irbesartan" title="Irbesartan">irbesartan</a>, <a href="Olmesartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Olmesartan" title="Olmesartan">olmesartan</a>, and <a href="Telmisartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Telmisartan" title="Telmisartan">telmisartan</a>. They all have the same mechanism of action and potentially inhibit the actions of angiotensin better than ACE inhibitors, such as <a href="Lisinopril.htm" tppabs="https://ptable.com/wiki/compounds/A/Lisinopril" title="Lisinopril">lisinopril</a>, because there are other enzymes than ACE that have the capability of producing angiotensin II.<span class="mw-ref" id="cite_ref-:1_34-2"><a href="#cite_note-:1-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span></p>

<p>Losartan is a uricosuric. As a specific inhibitor of the urate transporter 1 (SLC22A12, URAT1), losartan blocks the uptake of uric acid into cells, thus leaving more available in the bloodstream to be filtered and excreted by the kidneys.<span class="mw-ref" id="cite_ref-36"><a href="#cite_note-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span> Because losartan can cause hyperkalemia, individuals should not use <a href="Potassium.htm" tppabs="https://ptable.com/wiki/compounds/A/Potassium" title="Potassium">potassium</a> supplements or salt substitutes containing potassium without appropriate monitoring by a physician.<span class="mw-ref" id="cite_ref-37"><a href="#cite_note-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacokinetics">Pharmacokinetics</h2></summary>
    
<p>Losartan is well absorbed following oral administration and undergoes significant first-pass metabolism to produce the 5-carboxylic acid metabolite, designated as EXP3174. About 14% of an oral dosage is converted to this metabolite, which is long-acting (6 to 8 hr) and a noncompetitive antagonist at the AT<sub>1</sub> receptor, contributing to the pharmacological effects of losartan. EXP3174 is 10-40 times more potent in blocking AT<sub>1</sub> receptors than losartan. In addition, the binding to the target enzyme is pH-sensitive, and the negatively-charged tetrazole ring, which is similar in size to the negative carboxylic acid derivative, may contribute to the activity of the drug.<span class="mw-ref" id="cite_ref-38"><a href="#cite_note-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span></p>

<p>Losartan's bioavailability is about 33%.</p>

<p>Metabolism is primarily by cytochrome P450 isoenzymes CYP2C9 and CYP3A4. Peak plasma concentrations of losartan and EXP3174 occur about one hour and three to four hours, respectively, after an oral dose. Both losartan and EXP3174 are more than 98% bound to plasma proteins. Losartan is excreted in the urine, and in the feces via bile, as unchanged drug and metabolites. About 4% of an oral dose is excreted unchanged in urine, and about 6% is excreted in urine as the active metabolite. The terminal elimination half lives of losartan and EXP3174 are about 1.5 to 2.5 hours and 3 to 9 hours, respectively.</p>

<p>Losartan and other angiotensin-receptor antagonists exhibit fetal toxicity and should be avoided during pregnancy, particularly in the second and third trimesters.<span class="mw-ref" id="cite_ref-pmid16029066_39-0"><a href="#cite_note-pmid16029066-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Chemistry">Chemistry</h2></summary>
    
<p>Losartan is generally marketed as the (basic) potassium salt of the aromatized negatively charged <a href="Tetrazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Tetrazole" title="Tetrazole">tetrazole</a>, called "losartan potassium".<span class="mw-ref" id="cite_ref-40"><a href="#cite_note-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<ul><li>Discovery and development of angiotensin receptor blockers</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Dosing">Dosing</h2></summary>
    
<p>The suggested initial dose of losartan for treatment of hypertension is 50<span>&nbsp;</span>mg/day, and the usual maintenance dose range is 25–100<span>&nbsp;</span>mg/day.<span class="mw-ref" id="cite_ref-:1_34-3"><a href="#cite_note-:1-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span> There is limited data on what dosage is considered toxic in humans; toxicity would most likely result in decreased blood pressure and an increased heart rate.<span class="mw-ref" id="cite_ref-Cozaar_FDA_label_9-10"><a href="#cite_note-Cozaar_FDA_label-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    

<p>A hypothesis emerged in an opinion commentary published in March 2020, that AT1R blockers such as losartan may work to mitigate the symptoms of COVID-19 (SARS-CoV-2) infection.<span class="mw-ref" id="cite_ref-41"><a href="#cite_note-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span> Competing hypotheses are that it will make the symptoms worse.<span class="mw-ref" id="cite_ref-42"><a href="#cite_note-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span><span class="mw-ref" id="cite_ref-43"><a href="#cite_note-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span> A study of this question was started in March 2020.<span class="mw-ref" id="cite_ref-44"><a href="#cite_note-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-Pregnancy-1"> <span id="mw-reference-text-cite_note-Pregnancy-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/losartan.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/losartan.html'" tppabs="https://www.drugs.com/pregnancy/losartan.html" class="external text external">"Losartan (Cozaar) Use During Pregnancy"</a>. <i>Drugs.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">10 December</span> 2017</span>.</cite></span></li><li id="cite_note-AHFS2017-2"> <span id="mw-reference-text-cite_note-AHFS2017-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/losartan-potassium.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/losartan-potassium.html'" tppabs="https://www.drugs.com/monograph/losartan-potassium.html" class="external text external">"Losartan Potassium"</a>. The American Society of Health-System Pharmacists<span class="reference-accessdate">. Retrieved <span class="nowrap">8 December</span> 2017</span>.</cite></span></li><li id="cite_note-Fis2006-3"> <span id="mw-reference-text-cite_note-Fis2006-3" class="mw-reference-text"><cite id="CITEREFFischerGanellin2006" class="citation book cs1">Fischer, Jnos; Ganellin, C. Robin (2006). <a href="javascript:if(confirm('https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA470  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA470'" tppabs="https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA470" class="external text external"><i>Analogue-based Drug Discovery</i></a>. John Wiley &amp; Sons. p.<span>&nbsp;</span>470. ISBN<span>&nbsp;</span><bdi>9783527607495</bdi>.</cite></span></li><li id="cite_note-WHO21st-4"> <span id="mw-reference-text-cite_note-WHO21st-4" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2019" class="citation book cs1">World Health Organization (2019). <i>World Health Organization model list of essential medicines: 21st list 2019</i>. Geneva: World Health Organization. hdl:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://hdl.handle.net/10665%2F325771  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F325771'" tppabs="https://hdl.handle.net/10665%2F325771" class="external text external">10665/325771</a></span>. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.</cite></span></li><li id="cite_note-BNF69-5"> <span id="mw-reference-text-cite_note-BNF69-5" class="mw-reference-text"><cite class="citation book cs1"><i>British national formulary<span>&nbsp;</span>: BNF 69</i> (69 ed.). British Medical Association. 2015. p.<span>&nbsp;</span>127. ISBN<span>&nbsp;</span><bdi>9780857111562</bdi>.</cite></span></li><li id="cite_note-Top300Drugs-6"> <span id="mw-reference-text-cite_note-Top300Drugs-6" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Top300Drugs.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Top300Drugs.aspx'" tppabs="https://clincalc.com/DrugStats/Top300Drugs.aspx" class="external text external">"The Top 300 of 2020"</a>. <i>ClinCalc</i><span class="reference-accessdate">. Retrieved <span class="nowrap">11 April</span> 2020</span>.</cite></span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Drugs/LosartanPotassium  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Drugs/LosartanPotassium'" tppabs="https://clincalc.com/DrugStats/Drugs/LosartanPotassium" class="external text external">"Losartan Potassium - Drug Usage Statistics"</a>. <i>ClinCalc</i>. 23 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">11 April</span> 2020</span>.</cite></span></li><li id="cite_note-8"> <span id="mw-reference-text-cite_note-8" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Drugs/HydrochlorothiazideLosartanPotassium  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Drugs/HydrochlorothiazideLosartanPotassium'" tppabs="https://clincalc.com/DrugStats/Drugs/HydrochlorothiazideLosartanPotassium" class="external text external">"Hydrochlorothiazide; Losartan Potassium - Drug Usage Statistics"</a>. <i>ClinCalc</i>. 23 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">11 April</span> 2020</span>.</cite></span></li><li id="cite_note-Cozaar_FDA_label-9"> <span id="mw-reference-text-cite_note-Cozaar_FDA_label-9" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ac32c20-169d-475a-fc8a-934f758d6ab0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ac32c20-169d-475a-fc8a-934f758d6ab0'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ac32c20-169d-475a-fc8a-934f758d6ab0" class="external text external">"Cozaar- losartan potassium tablet, film coated"</a>. <i>DailyMed</i>. 14 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">20 March</span> 2020</span>.</cite></span></li><li id="cite_note-pmid16761901-10"> <span id="mw-reference-text-cite_note-pmid16761901-10" class="mw-reference-text"><cite id="CITEREFBoersmaAtthobariGansevoortde_Jong-Van_den_Berg2006" class="citation journal cs1">Boersma C, Atthobari J, Gansevoort RT, de Jong-Van den Berg LT, de Jong PE, de Zeeuw D, Annemans LJ, Postma MJ (2006). "Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making". <i>PharmacoEconomics</i>. <b>24</b> (6): 523–35. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00019053-200624060-00001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00019053-200624060-00001'" tppabs="https://doi.org/10.2165%2F00019053-200624060-00001" class="external text external">10.2165/00019053-200624060-00001</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16761901  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16761901'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16761901" class="external text external">16761901</a>.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.nice.org.uk/guidance/cg127/chapter/1-Guidance  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nice.org.uk/guidance/cg127/chapter/1-Guidance#choosing-antihypertensive-drug-treatment-2'" tppabs="https://www.nice.org.uk/guidance/cg127/chapter/1-Guidance#choosing-antihypertensive-drug-treatment-2" class="external text external">"Hypertension in adults: diagnosis and management"</a>. <i>National Institute for Health and Care Excellence (NICE)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">8 April</span> 2017</span>.</cite></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite id="CITEREFAbrams_A2007" class="citation book cs1">Abrams A (2007). <a href="javascript:if(confirm('https://archive.org/details/clinicaldrugther0008abra/page/846  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/clinicaldrugther0008abra/page/846'" tppabs="https://archive.org/details/clinicaldrugther0008abra/page/846" class="external text external"><i>'Clinical Drug Therapy Rationales for Nursing Practice</i></a>. Philadelphia, Pa.: Lippincott Williams &amp; Wilkins. p.<span>&nbsp;</span><a href="javascript:if(confirm('https://archive.org/details/clinicaldrugther0008abra/page/846  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/clinicaldrugther0008abra/page/846'" tppabs="https://archive.org/details/clinicaldrugther0008abra/page/846" class="external text external">846</a>. ISBN<span>&nbsp;</span><bdi>978-0-7817-6263-2</bdi>.</cite></span></li><li id="cite_note-Cheungpasitporn2015-13"> <span id="mw-reference-text-cite_note-Cheungpasitporn2015-13" class="mw-reference-text"><cite id="CITEREFCheungpasitpornThongprayoonChiasakulKorpaisarn2015" class="citation journal cs1">Cheungpasitporn, W; Thongprayoon, C; Chiasakul, T; Korpaisarn, S; Erickson, SB (November 2015). <a href="javascript:if(confirm('https://doi.org/10.1093/qjmed/hcv049  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093/qjmed/hcv049'" tppabs="https://doi.org/10.1093/qjmed/hcv049" class="external text external">"Renin-angiotensin system inhibitors linked to anemia: a systematic review and meta-analysis"</a>. <i>QJM<span>&nbsp;</span>: Monthly Journal of the Association of Physicians</i>. <b>108</b> (11): 879–84. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1093%2Fqjmed%2Fhcv049  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Fqjmed%2Fhcv049'" tppabs="https://doi.org/10.1093%2Fqjmed%2Fhcv049" class="external text external">10.1093/qjmed/hcv049</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25697787  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25697787'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25697787" class="external text external">25697787</a>.</cite> <span style="position:relative; top: -2px;"><figure-inline><img src="../I/m/Open_Access_logo_PLoS_transparent.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Open_Access_logo_PLoS_transparent.svg.png" data-file-width="640" data-file-height="1000" data-file-type="drawing" height="14" width="9"></figure-inline></span></span></li><li id="cite_note-14"> <span id="mw-reference-text-cite_note-14" class="mw-reference-text"><cite id="CITEREFPattiSinhaSharmaYoon2019" class="citation journal cs1">Patti R, Sinha A, Sharma S, Yoon TS, Kupfer Y (May 2019). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663042  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663042'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663042" class="external text external">"Losartan-induced severe hepatic injury: A case report and literature review"</a>. <i>Cureus</i>. <b>11</b> (5): e4769. doi:<a href="javascript:if(confirm('https://doi.org/10.7759%2Fcureus.4769  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.7759%2Fcureus.4769'" tppabs="https://doi.org/10.7759%2Fcureus.4769" class="external text external">10.7759/cureus.4769</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663042  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663042'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663042" class="external text external">6663042</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/31363450  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/31363450'" tppabs="https://pubmed.ncbi.nlm.nih.gov/31363450" class="external text external">31363450</a>.</cite></span></li><li id="cite_note-fda-15"> <span id="mw-reference-text-cite_note-fda-15" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://wayback.archive-it.org/7993/20170112172842/https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm169666.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://wayback.archive-it.org/7993/20170112172842/https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm169666.htm'" tppabs="https://wayback.archive-it.org/7993/20170112172842/https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm169666.htm" class="external text external">"Cozaar (losartan potassium) 25 mg, 50 mg, and 100 mg Tablets"</a>. U.S. Food and Drug Administration (FDA). 16 October 2014. Archived from <a href="javascript:if(confirm('https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm169666.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm169666.htm'" tppabs="https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm169666.htm" class="external text external">the original</a> on 12 January 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">21 July</span> 2015</span>.</cite></span></li><li id="cite_note-16"> <span id="mw-reference-text-cite_note-16" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.fda.gov/news-events/press-announcements/fda-provides-update-its-ongoing-investigation-arb-drug-products-reports-finding-new-nitrosamine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/news-events/press-announcements/fda-provides-update-its-ongoing-investigation-arb-drug-products-reports-finding-new-nitrosamine'" tppabs="https://www.fda.gov/news-events/press-announcements/fda-provides-update-its-ongoing-investigation-arb-drug-products-reports-finding-new-nitrosamine" class="external text external">"FDA provides update on its ongoing investigation into ARB drug products; reports on finding of a new nitrosamine impurity in certain lots of losartan and product recall"</a> (Press release). U.S. Food and Drug Administration (FDA). 3 October 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191003084728/https://www.fda.gov/news-events/press-announcements/fda-provides-update-its-ongoing-investigation-arb-drug-products-reports-finding-new-nitrosamine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191003084728/https://www.fda.gov/news-events/press-announcements/fda-provides-update-its-ongoing-investigation-arb-drug-products-reports-finding-new-nitrosamine'" tppabs="https://web.archive.org/web/20191003084728/https://www.fda.gov/news-events/press-announcements/fda-provides-update-its-ongoing-investigation-arb-drug-products-reports-finding-new-nitrosamine" class="external text external">Archived</a> from the original on 3 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">3 October</span> 2019</span>.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-voluntary-nationwide-recall-one-lot-losartan-potassium-and-hydrochlorothiazide-due  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-voluntary-nationwide-recall-one-lot-losartan-potassium-and-hydrochlorothiazide-due'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-voluntary-nationwide-recall-one-lot-losartan-potassium-and-hydrochlorothiazide-due" class="external text external">"Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)"</a>. U.S. Food and Drug Administration (FDA). 8 November 2018. <a href="javascript:if(confirm('https://web.archive.org/web/20190907103710/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-voluntary-nationwide-recall-one-lot-losartan-potassium-and-hydrochlorothiazide-due  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190907103710/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-voluntary-nationwide-recall-one-lot-losartan-potassium-and-hydrochlorothiazide-due'" tppabs="https://web.archive.org/web/20190907103710/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-voluntary-nationwide-recall-one-lot-losartan-potassium-and-hydrochlorothiazide-due" class="external text external">Archived</a> from the original on 7 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 October</span> 2019</span>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium-tablets-usp  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium-tablets-usp'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium-tablets-usp" class="external text external">"Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP"</a>. U.S. Food and Drug Administration (FDA). 20 December 2018. <a href="javascript:if(confirm('https://web.archive.org/web/20190907100508/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium-tablets-usp  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190907100508/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium-tablets-usp'" tppabs="https://web.archive.org/web/20190907100508/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium-tablets-usp" class="external text external">Archived</a> from the original on 7 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 October</span> 2019</span>.</cite></span></li><li id="cite_note-19"> <span id="mw-reference-text-cite_note-19" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-tablets-usp  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-tablets-usp'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-tablets-usp" class="external text external">"Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP"</a>. U.S. Food and Drug Administration (FDA). 3 January 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190907095806/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-tablets-usp  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190907095806/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-tablets-usp'" tppabs="https://web.archive.org/web/20190907095806/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-tablets-usp" class="external text external">Archived</a> from the original on 7 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 October</span> 2019</span>.</cite></span></li><li id="cite_note-20"> <span id="mw-reference-text-cite_note-20" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium" class="external text external">"UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP"</a>. U.S. Food and Drug Administration (FDA). 22 January 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190907094808/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190907094808/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium'" tppabs="https://web.archive.org/web/20190907094808/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium" class="external text external">Archived</a> from the original on 7 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 October</span> 2019</span>.</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium-0'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium-0" class="external text external">"Updated: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium /Hydrochlorothiazide Tablets, USP"</a>. U.S. Food and Drug Administration (FDA). 1 March 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190907092810/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190907092810/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium-0'" tppabs="https://web.archive.org/web/20190907092810/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-issues-voluntary-nationwide-recall-losartan-potassium-0" class="external text external">Archived</a> from the original on 7 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 October</span> 2019</span>.</cite></span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium" class="external text external">"Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium/Hydrochlorothiazide Tablets, USP"</a>. U.S. Food and Drug Administration (FDA). 18 April 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191006035036/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191006035036/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium'" tppabs="https://web.archive.org/web/20191006035036/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium" class="external text external">Archived</a> from the original on 6 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 October</span> 2019</span>.</cite></span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-0'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-0" class="external text external">"Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium / Hydrochlorothiazide Tablets, USP"</a>. U.S. Food and Drug Administration (FDA). 23 September 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191006034633/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191006034633/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-0'" tppabs="https://web.archive.org/web/20191006034633/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-0" class="external text external">Archived</a> from the original on 6 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">23 September</span> 2019</span>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-expands-voluntary-nationwide-recall-losartan-potassium-tablets  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-expands-voluntary-nationwide-recall-losartan-potassium-tablets'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-expands-voluntary-nationwide-recall-losartan-potassium-tablets" class="external text external">"Legacy Pharmaceutical Packaging, LLC Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity Found in the Active Pharmaceutical Ingredient (API)"</a>. U.S. Food and Drug Administration (FDA). 15 July 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190913232047/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-expands-voluntary-nationwide-recall-losartan-potassium-tablets  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190913232047/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-expands-voluntary-nationwide-recall-losartan-potassium-tablets'" tppabs="https://web.archive.org/web/20190913232047/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-expands-voluntary-nationwide-recall-losartan-potassium-tablets" class="external text external">Archived</a> from the original on 13 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 October</span> 2019</span>.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/macleods-pharmaceutical-limited-issues-voluntary-nationwide-consumer-level-recall-losartan-potassium  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/macleods-pharmaceutical-limited-issues-voluntary-nationwide-consumer-level-recall-losartan-potassium'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/macleods-pharmaceutical-limited-issues-voluntary-nationwide-consumer-level-recall-losartan-potassium" class="external text external">"Macleods Pharmaceutical Limited Issues Voluntary Nationwide Consumer Level Recall of Losartan Potassium 50mg and Losartan Potassium/Hydrochlorothiazide combination Tablets 50mg/12.5mg, 100mg/12.5mg and 100mg/25mg due to detection of NMBA (N-Nitroso-N-Methyl-4-aminobutyric acid) Impurity"</a>. U.S. Food and Drug Administration (FDA). 26 June 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191001203725/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/macleods-pharmaceutical-limited-issues-voluntary-nationwide-consumer-level-recall-losartan-potassium  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191001203725/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/macleods-pharmaceutical-limited-issues-voluntary-nationwide-consumer-level-recall-losartan-potassium'" tppabs="https://web.archive.org/web/20191001203725/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/macleods-pharmaceutical-limited-issues-voluntary-nationwide-consumer-level-recall-losartan-potassium" class="external text external">Archived</a> from the original on 1 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 October</span> 2019</span>.</cite></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-pharmaceuticals-usa-inc-expands-voluntary-nationwide-recall-losartan-potassium-50-mg-and-100-mg  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-pharmaceuticals-usa-inc-expands-voluntary-nationwide-recall-losartan-potassium-50-mg-and-100-mg'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-pharmaceuticals-usa-inc-expands-voluntary-nationwide-recall-losartan-potassium-50-mg-and-100-mg" class="external text external">"Teva Pharmaceuticals USA, Inc. Expands Voluntary Nationwide Recall of Losartan Potassium to 50 mg and 100 mg Tablets USP, Sold Exclusively to Golden State Medical Supply, Inc"</a>. U.S. Food and Drug Administration (FDA). 11 June 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190913232046/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-pharmaceuticals-usa-inc-expands-voluntary-nationwide-recall-losartan-potassium-50-mg-and-100-mg  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190913232046/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-pharmaceuticals-usa-inc-expands-voluntary-nationwide-recall-losartan-potassium-50-mg-and-100-mg'" tppabs="https://web.archive.org/web/20190913232046/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-pharmaceuticals-usa-inc-expands-voluntary-nationwide-recall-losartan-potassium-50-mg-and-100-mg" class="external text external">Archived</a> from the original on 13 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 October</span> 2019</span>.</cite></span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vivimed-life-sciences-pvt-ltd-issues-voluntary-nationwide-recall-losartan-potassium-25-mg-50-mg-and  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vivimed-life-sciences-pvt-ltd-issues-voluntary-nationwide-recall-losartan-potassium-25-mg-50-mg-and'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vivimed-life-sciences-pvt-ltd-issues-voluntary-nationwide-recall-losartan-potassium-25-mg-50-mg-and" class="external text external">"Vivimed Life Sciences Pvt Ltd Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg, 50 mg and 100 mg Tablets, USP Due to the Detection of Trace Amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) Impurity"</a>. U.S. Food and Drug Administration (FDA). 3 May 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190913232045/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vivimed-life-sciences-pvt-ltd-issues-voluntary-nationwide-recall-losartan-potassium-25-mg-50-mg-and  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190913232045/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vivimed-life-sciences-pvt-ltd-issues-voluntary-nationwide-recall-losartan-potassium-25-mg-50-mg-and'" tppabs="https://web.archive.org/web/20190913232045/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vivimed-life-sciences-pvt-ltd-issues-voluntary-nationwide-recall-losartan-potassium-25-mg-50-mg-and" class="external text external">Archived</a> from the original on 13 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 October</span> 2019</span>.</cite></span></li><li id="cite_note-28"> <span id="mw-reference-text-cite_note-28" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-pharmaceuticals-usa-inc-issues-voluntary-nationwide-recall-losartan-potassium-25-mg-and-100-mg  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-pharmaceuticals-usa-inc-issues-voluntary-nationwide-recall-losartan-potassium-25-mg-and-100-mg'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-pharmaceuticals-usa-inc-issues-voluntary-nationwide-recall-losartan-potassium-25-mg-and-100-mg" class="external text external">"Teva Pharmaceuticals USA, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg and 100 mg Tablets USP, Sold Exclusively to Golden State Medical Supply"</a>. U.S. Food and Drug Administration (FDA). 26 April 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190913232043/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-pharmaceuticals-usa-inc-issues-voluntary-nationwide-recall-losartan-potassium-25-mg-and-100-mg  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190913232043/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-pharmaceuticals-usa-inc-issues-voluntary-nationwide-recall-losartan-potassium-25-mg-and-100-mg'" tppabs="https://web.archive.org/web/20190913232043/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-pharmaceuticals-usa-inc-issues-voluntary-nationwide-recall-losartan-potassium-25-mg-and-100-mg" class="external text external">Archived</a> from the original on 13 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 October</span> 2019</span>.</cite></span></li><li id="cite_note-29"> <span id="mw-reference-text-cite_note-29" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets" class="external text external">"Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmaceutical Ingredient (API)"</a>. U.S. Food and Drug Administration (FDA). 19 March 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190907091705/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190907091705/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets'" tppabs="https://web.archive.org/web/20190907091705/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets" class="external text external">Archived</a> from the original on 7 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 October</span> 2019</span>.</cite></span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-0'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-0" class="external text external">"Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, and 100mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in the Active Pharmaceutical Ingredient (API)"</a>. U.S. Food and Drug Administration (FDA). 28 March 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190907091211/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190907091211/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-0'" tppabs="https://web.archive.org/web/20190907091211/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-0" class="external text external">Archived</a> from the original on 7 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 October</span> 2019</span>.</cite></span></li><li id="cite_note-31"> <span id="mw-reference-text-cite_note-31" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-1'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-1" class="external text external">"Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient (API)"</a>. U.S. Food and Drug Administration (FDA). 15 March 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190907091917/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190907091917/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-1'" tppabs="https://web.archive.org/web/20190907091917/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/legacy-pharmaceutical-packaging-llc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-1" class="external text external">Archived</a> from the original on 7 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 October</span> 2019</span>.</cite></span></li><li id="cite_note-32"> <span id="mw-reference-text-cite_note-32" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/camber-pharmaceuticals-inc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-usp-25-mg  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/camber-pharmaceuticals-inc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-usp-25-mg'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/camber-pharmaceuticals-inc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-usp-25-mg" class="external text external">"Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25 mg, 50 mg and 100 mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient (API)"</a>. U.S. Food and Drug Administration (FDA). 28 February 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190907092842/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/camber-pharmaceuticals-inc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-usp-25-mg  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190907092842/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/camber-pharmaceuticals-inc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-usp-25-mg'" tppabs="https://web.archive.org/web/20190907092842/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/camber-pharmaceuticals-inc-issues-voluntary-nationwide-recall-losartan-potassium-tablets-usp-25-mg" class="external text external">Archived</a> from the original on 7 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 October</span> 2019</span>.</cite></span></li><li id="cite_note-33"> <span id="mw-reference-text-cite_note-33" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/macleods-pharmaceuticals-limited-issues-voluntary-nationwide-consumer-level-recall-one-lot-blm-715a  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/macleods-pharmaceuticals-limited-issues-voluntary-nationwide-consumer-level-recall-one-lot-blm-715a'" tppabs="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/macleods-pharmaceuticals-limited-issues-voluntary-nationwide-consumer-level-recall-one-lot-blm-715a" class="external text external">"Macleods Pharmaceuticals Limited Issues Voluntary Nationwide Consumer Level Recall of One Lot (BLM 715A) of Losartan Potassium/Hydrochlorothiazide Combination Tablets 100mg/25mg Due to detection of NDEA (N-Nitrosodiethylamine) Impurity"</a>. U.S. Food and Drug Administration (FDA). 22 February 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20190907093351/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/macleods-pharmaceuticals-limited-issues-voluntary-nationwide-consumer-level-recall-one-lot-blm-715a  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190907093351/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/macleods-pharmaceuticals-limited-issues-voluntary-nationwide-consumer-level-recall-one-lot-blm-715a'" tppabs="https://web.archive.org/web/20190907093351/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/macleods-pharmaceuticals-limited-issues-voluntary-nationwide-consumer-level-recall-one-lot-blm-715a" class="external text external">Archived</a> from the original on 7 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 October</span> 2019</span>.</cite></span></li><li id="cite_note-:1-34"> <span id="mw-reference-text-cite_note-:1-34" class="mw-reference-text"><cite id="CITEREFKatzung,_Bertram_G.,_editor2017" class="citation book cs1">Katzung, Bertram G., editor (30 November 2017). <i>Basic &amp; clinical pharmacology</i>. ISBN<span>&nbsp;</span><bdi>9781259641152</bdi>. OCLC<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/oclc/1048625746  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/oclc/1048625746'" tppabs="https://www.worldcat.org/oclc/1048625746" class="external text external">1048625746</a>.</cite><span class="cs1-maint citation-comment">CS1 maint: multiple names: authors list (link)</span></span></li><li id="cite_note-35"> <span id="mw-reference-text-cite_note-35" class="mw-reference-text"><cite id="CITEREFGraudalHubeck-GraudalJürgens2012" class="citation journal cs1">Graudal, Niels A.; Hubeck-Graudal, Thorbjørn; Jürgens, Gesche (January 2012). <a href="javascript:if(confirm('https://doi.org/10.1038/ajh.2011.210  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038/ajh.2011.210'" tppabs="https://doi.org/10.1038/ajh.2011.210" class="external text external">"Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review)"</a>. <i>American Journal of Hypertension</i>. <b>25</b> (1): 1–15. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1038%2Fajh.2011.210  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fajh.2011.210'" tppabs="https://doi.org/10.1038%2Fajh.2011.210" class="external text external">10.1038/ajh.2011.210</a></span>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1941-7225  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1941-7225'" tppabs="https://www.worldcat.org/issn/1941-7225" class="external text external">1941-7225</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22068710  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22068710'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22068710" class="external text external">22068710</a>.</cite></span></li><li id="cite_note-36"> <span id="mw-reference-text-cite_note-36" class="mw-reference-text"><cite id="CITEREFHamadaIchidaHosoyamadaMizuta2008" class="citation journal cs1">Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K,  et al. (1 October 2008). <a href="javascript:if(confirm('https://doi.org/10.1038/ajh.2008.245  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038/ajh.2008.245'" tppabs="https://doi.org/10.1038/ajh.2008.245" class="external text external">"Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients"</a>. <i>American Journal of Hypertension</i>. <b>21</b> (10): 1157–1162. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1038%2Fajh.2008.245  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fajh.2008.245'" tppabs="https://doi.org/10.1038%2Fajh.2008.245" class="external text external">10.1038/ajh.2008.245</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18670416  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18670416'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18670416" class="external text external">18670416</a>.</cite></span></li><li id="cite_note-37"> <span id="mw-reference-text-cite_note-37" class="mw-reference-text">RxList. The Internet Drug Index. <a href="javascript:if(confirm('http://www.rxlist.com/cozaar-drug/clinical-pharmacology.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.rxlist.com/cozaar-drug/clinical-pharmacology.htm'" tppabs="http://www.rxlist.com/cozaar-drug/clinical-pharmacology.htm" class="external text external">Clinical pharmacology of Cozaar</a>. Retrieved January 6, 2014.</span></li><li id="cite_note-38"> <span id="mw-reference-text-cite_note-38" class="mw-reference-text"><a href="javascript:if(confirm('http://www.jbc.org/content/270/5/2284.long  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.jbc.org/content/270/5/2284.long'" tppabs="http://www.jbc.org/content/270/5/2284.long" class="external text external">Binding of losartan</a></span></li><li id="cite_note-pmid16029066-39"> <span id="mw-reference-text-cite_note-pmid16029066-39" class="mw-reference-text"><cite id="CITEREFSicaGehrGhosh2005" class="citation journal cs1">Sica DA, Gehr TW, Ghosh S (2005). "Clinical pharmacokinetics of losartan". <i>Clin Pharmacokinet</i>. <b>44</b> (8): 797–814. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003088-200544080-00003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003088-200544080-00003'" tppabs="https://doi.org/10.2165%2F00003088-200544080-00003" class="external text external">10.2165/00003088-200544080-00003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16029066  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16029066'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16029066" class="external text external">16029066</a>.</cite></span></li><li id="cite_note-40"> <span id="mw-reference-text-cite_note-40" class="mw-reference-text"><a href="javascript:if(confirm('https://www.rxlist.com/cozaar-drug.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.rxlist.com/cozaar-drug.htm'" tppabs="https://www.rxlist.com/cozaar-drug.htm" class="external text external">see negatively charged tetrazole structure</a></span></li><li id="cite_note-41"> <span id="mw-reference-text-cite_note-41" class="mw-reference-text"><cite id="CITEREFGurwitz2020" class="citation journal cs1">Gurwitz D (March 2020). <a href="javascript:if(confirm('https://doi.org/10.1002/ddr.21656  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002/ddr.21656'" tppabs="https://doi.org/10.1002/ddr.21656" class="external text external">"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics"</a>. <i>Drug Development Research</i>. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1002%2Fddr.21656  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fddr.21656'" tppabs="https://doi.org/10.1002%2Fddr.21656" class="external text external">10.1002/ddr.21656</a></span>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1098-2299  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1098-2299'" tppabs="https://www.worldcat.org/issn/1098-2299" class="external text external">1098-2299</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/32129518  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/32129518'" tppabs="https://pubmed.ncbi.nlm.nih.gov/32129518" class="external text external">32129518</a>.</cite></span></li><li id="cite_note-42"> <span id="mw-reference-text-cite_note-42" class="mw-reference-text"><cite id="CITEREFWatkins2020" class="citation journal cs1">Watkins, John (28 February 2020). <a href="javascript:if(confirm('https://www.bmj.com/content/368/bmj.m810/rr-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.bmj.com/content/368/bmj.m810/rr-2'" tppabs="https://www.bmj.com/content/368/bmj.m810/rr-2" class="external text external">"Preventing a covid-19 pandemic"</a>. <i>BMJ</i>: m810. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1136%2Fbmj.m810  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fbmj.m810'" tppabs="https://doi.org/10.1136%2Fbmj.m810" class="external text external">10.1136/bmj.m810</a></span>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1756-1833  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1756-1833'" tppabs="https://www.worldcat.org/issn/1756-1833" class="external text external">1756-1833</a>.</cite></span></li><li id="cite_note-43"> <span id="mw-reference-text-cite_note-43" class="mw-reference-text"><cite id="CITEREFKickbuschLeung2020" class="citation journal cs1">Kickbusch, Ilona; Leung, Gabriel (31 January 2020). <a href="javascript:if(confirm('https://www.bmj.com/content/368/bmj.m406/rr-11  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.bmj.com/content/368/bmj.m406/rr-11'" tppabs="https://www.bmj.com/content/368/bmj.m406/rr-11" class="external text external">"Response to the emerging novel coronavirus outbreak"</a>. <i>BMJ</i>: m406. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1136%2Fbmj.m406  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fbmj.m406'" tppabs="https://doi.org/10.1136%2Fbmj.m406" class="external text external">10.1136/bmj.m406</a></span>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1756-1833  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1756-1833'" tppabs="https://www.worldcat.org/issn/1756-1833" class="external text external">1756-1833</a>.</cite></span></li><li id="cite_note-44"> <span id="mw-reference-text-cite_note-44" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clinicaltrials.gov/ct2/show/NCT04312009  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clinicaltrials.gov/ct2/show/NCT04312009'" tppabs="https://clinicaltrials.gov/ct2/show/NCT04312009" class="external text external">"Losartan for Patients With COVID-19 Requiring Hospitalization"</a>. <i>ClinicalTrials.gov</i>. 17 March 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">23 March</span> 2020</span>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Further_reading">Further reading</h2></summary>
    
<ul><li><cite id="CITEREFAl-MajedAssiriKhalilAbdel-Aziz2015" class="citation journal cs1">Al-Majed AR, Assiri E, Khalil NY, Abdel-Aziz HA (2015). "Losartan: Comprehensive Profile". <i>Profiles Drug Subst Excip Relat Methodol</i>. <b>40</b>: 159–94. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fbs.podrm.2015.02.003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fbs.podrm.2015.02.003'" tppabs="https://doi.org/10.1016%2Fbs.podrm.2015.02.003" class="external text external">10.1016/bs.podrm.2015.02.003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26051686  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26051686'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26051686" class="external text external">26051686</a>.</cite></li>
<li><cite class="citation journal cs1">Sica DA, Gehr TW, Ghosh S (2005). "Clinical pharmacokinetics of losartan". <i>Clin Pharmacokinet</i>. <b>44</b> (8): 797–814. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003088-200544080-00003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003088-200544080-00003'" tppabs="https://doi.org/10.2165%2F00003088-200544080-00003" class="external text external">10.2165/00003088-200544080-00003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16029066  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16029066'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16029066" class="external text external">16029066</a>.</cite></li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/losartan  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/losartan'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/losartan" class="external text external">"Losartan"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Merck_&amp;amp;_Co.,_Inc." style="padding:3px"><table class="nowraplinks hlist mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Merck_&amp;amp;_Co.,_Inc." style="font-size:114%;margin:0 4em">Merck &amp; Co., Inc.</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Corporate directors:</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Richard Clark</li>
<li>Johnnetta Cole</li>
<li>William Harrison</li>
<li><span class="new">William Kelley</span></li>
<li>Rochelle Lazarus</li>
<li>Thomas Shenk</li>
<li><span class="new">Anne Tatlock</span></li>
<li>Samuel Thier</li>
<li>Wendell Weeks</li>
<li><span class="new">Peter Wendell</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Products:</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Alendronic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Alendronic_acid" title="Alendronic acid">Alendronate</a></li>
<li><a href="Aprepitant.htm" tppabs="https://ptable.com/wiki/compounds/A/Aprepitant" title="Aprepitant">Aprepitant</a></li>
<li><a href="Ertapenem.htm" tppabs="https://ptable.com/wiki/compounds/A/Ertapenem" title="Ertapenem">Ertapenem</a></li>
<li><a href="Ezetimibe.htm" tppabs="https://ptable.com/wiki/compounds/A/Ezetimibe" title="Ezetimibe">Ezetimibe</a></li>
<li>Ezetimibe/simvastatin</li>
<li><a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">Finasteride</a></li>
<li>Fosaprepitant</li>
<li><a href="Indinavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Indinavir" title="Indinavir">Indinavir</a></li>
<li><a href="Losartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Losartan" title="Losartan">Losartan</a></li>
<li><a href="Lovastatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Lovastatin" title="Lovastatin">Lovastatin</a></li>
<li><a href="Montelukast.htm" tppabs="https://ptable.com/wiki/compounds/A/Montelukast" title="Montelukast">Montelukast</a></li>
<li>Omarigliptin</li>
<li>Raltegravir</li>
<li><a href="Rizatriptan.htm" tppabs="https://ptable.com/wiki/compounds/A/Rizatriptan" title="Rizatriptan">Rizatriptan</a></li>
<li><a href="Rofecoxib.htm" tppabs="https://ptable.com/wiki/compounds/A/Rofecoxib" title="Rofecoxib">Rofecoxib</a></li>
<li>rVSV-ZEBOV vaccine</li>
<li><a href="Simvastatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Simvastatin" title="Simvastatin">Simvastatin</a></li>
<li><a href="Sitagliptin.htm" tppabs="https://ptable.com/wiki/compounds/A/Sitagliptin" title="Sitagliptin">Sitagliptin</a></li>
<li><a href="Vorinostat.htm" tppabs="https://ptable.com/wiki/compounds/A/Vorinostat" title="Vorinostat">Vorinostat</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Publications:</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>The Merck Manuals
<ul><li><i>Index</i></li>
<li><i>Manual</i></li>
<li><i>Veterinary</i></li>
<li><i>Geriatrics</i></li></ul></li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Antihypertensive_drugs_acting_on_the_renin–angiotensin_system_(C09)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Antihypertensive_drugs_acting_on_the_renin–angiotensin_system_(C09)" style="font-size:114%;margin:0 4em">Antihypertensive drugs acting on the renin–angiotensin system (C09)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">ACE inhibitors<br>("-pril")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Sulfhydryl-containing:</i> <a href="Captopril.htm" tppabs="https://ptable.com/wiki/compounds/A/Captopril" title="Captopril">Captopril</a></li>
<li>Rentiapril</li>
<li>Zofenopril</li></ul>

<ul><li><i>Dicarboxylate-containing: </i><a href="Enalapril.htm" tppabs="https://ptable.com/wiki/compounds/A/Enalapril" title="Enalapril">Enalapril</a><sup>#</sup></li>
<li><a href="Benazepril.htm" tppabs="https://ptable.com/wiki/compounds/A/Benazepril" title="Benazepril">Benazepril</a></li>
<li><a href="Cilazapril.htm" tppabs="https://ptable.com/wiki/compounds/A/Cilazapril" title="Cilazapril">Cilazapril</a></li>
<li>Delapril</li>
<li>Imidapril</li>
<li><a href="Lisinopril.htm" tppabs="https://ptable.com/wiki/compounds/A/Lisinopril" title="Lisinopril">Lisinopril</a> (+HCT)</li>
<li><a href="Moexipril.htm" tppabs="https://ptable.com/wiki/compounds/A/Moexipril" title="Moexipril">Moexipril</a></li>
<li><a href="Perindopril.htm" tppabs="https://ptable.com/wiki/compounds/A/Perindopril" title="Perindopril">Perindopril</a> (+indapamide)</li>
<li><a href="Quinapril.htm" tppabs="https://ptable.com/wiki/compounds/A/Quinapril" title="Quinapril">Quinapril</a> (+HCT)</li>
<li><a href="Ramipril.htm" tppabs="https://ptable.com/wiki/compounds/A/Ramipril" title="Ramipril">Ramipril</a></li>
<li><a href="Spirapril.htm" tppabs="https://ptable.com/wiki/compounds/A/Spirapril" title="Spirapril">Spirapril</a></li>
<li>Temocapril</li>
<li><a href="Trandolapril.htm" tppabs="https://ptable.com/wiki/compounds/A/Trandolapril" title="Trandolapril">Trandolapril</a></li></ul>

<ul><li><i>Phosphonate-containing</i>: Ceronapril</li>
<li><a href="Fosinopril.htm" tppabs="https://ptable.com/wiki/compounds/A/Fosinopril" title="Fosinopril">Fosinopril</a> (+HCT)</li></ul>

<ul><li><i>Other/ungrouped:</i> Alacepril</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">AIIRAs<br>("-sartan")</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Azilsartan</li>
<li><a href="Candesartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Candesartan" title="Candesartan">Candesartan</a></li>
<li><a href="Eprosartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Eprosartan" title="Eprosartan">Eprosartan</a></li>
<li>Fimasartan</li>
<li><a href="Irbesartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Irbesartan" title="Irbesartan">Irbesartan</a> (<a href="Irbesartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Irbesartan/hydrochlorothiazide" title="Irbesartan/hydrochlorothiazide" class="mw-redirect">+HCT</a>)</li>
<li><a href="Losartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Losartan" title="Losartan">Losartan</a> (+HCT)</li>
<li><a href="Olmesartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Olmesartan" title="Olmesartan">Olmesartan</a> (+amlodipine)</li>
<li><a href="Tasosartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Tasosartan" title="Tasosartan">Tasosartan</a><sup>§</sup></li>
<li><a href="Telmisartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Telmisartan" title="Telmisartan">Telmisartan</a> (+HCT)</li>
<li><a href="Valsartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Valsartan" title="Valsartan">Valsartan</a> (+HCT, +amlodipine)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Renin inhibitors<br>("-kiren")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Aliskiren.htm" tppabs="https://ptable.com/wiki/compounds/A/Aliskiren" title="Aliskiren">Aliskiren</a> (+amlodipine, +amlodipine and HCT)</li>
<li><a href="Remikiren.htm" tppabs="https://ptable.com/wiki/compounds/A/Remikiren" title="Remikiren">Remikiren</a><sup>§</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Dual ACE/NEP inhibitors</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Gemopatrilat</li>
<li><span class="new">Ilepatril</span></li>
<li>Omapatrilat</li>
<li><span class="new">Sampatrilat</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Neprilysin inhibitors</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Sacubitril (+valsartan)</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Angiotensin_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Angiotensin_receptor_modulators" style="font-size:114%;margin:0 4em">Angiotensin receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>ATR</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Angiotensin II</li>
<li>Angiotensin III</li>
<li>Angiotensin IV</li>
<li>L-163,491</li>
<li>Saralasin</li></ul>

<ul><li><i>Antagonists:</i> Abitesartan</li>
<li>Azilsartan</li>
<li><a href="Candesartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Candesartan" title="Candesartan">Candesartan</a></li>
<li><span class="new">Elisartan</span></li>
<li><span class="new">Embusartan</span></li>
<li><a href="Eprosartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Eprosartan" title="Eprosartan">Eprosartan</a></li>
<li><span class="new">EXP-3174</span></li>
<li>Fimasartan</li>
<li>Forasartan</li>
<li><a href="Irbesartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Irbesartan" title="Irbesartan">Irbesartan</a></li>
<li><a href="Losartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Losartan" title="Losartan">Losartan</a></li>
<li><span class="new">Milfasartan</span></li>
<li><a href="Olmesartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Olmesartan" title="Olmesartan">Olmesartan</a></li>
<li><span class="new">Olodanrigan</span></li>
<li><span class="new">PD123319</span></li>
<li><span class="new">Pomisartan</span></li>
<li><span class="new">Pratosartan</span></li>
<li><span class="new">Ripisartan</span></li>
<li><span class="new">Saprisartan</span></li>
<li><span class="new">Sparsentan</span></li>
<li><a href="Tasosartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Tasosartan" title="Tasosartan">Tasosartan</a></li>
<li><a href="Telmisartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Telmisartan" title="Telmisartan">Telmisartan</a></li>
<li><a href="Valsartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Valsartan" title="Valsartan">Valsartan</a></li>
<li><span class="new">Zolasartan</span></li></ul>

<ul><li><i><abbr>ACE</abbr> inhibitors:</i> Alacepril</li>
<li><a href="Benazepril.htm" tppabs="https://ptable.com/wiki/compounds/A/Benazepril" title="Benazepril">Benazepril</a></li>
<li><a href="Captopril.htm" tppabs="https://ptable.com/wiki/compounds/A/Captopril" title="Captopril">Captopril</a></li>
<li><a href="Cilazapril.htm" tppabs="https://ptable.com/wiki/compounds/A/Cilazapril" title="Cilazapril">Cilazapril</a></li>
<li>Delapril</li>
<li><a href="Enalapril.htm" tppabs="https://ptable.com/wiki/compounds/A/Enalapril" title="Enalapril">Enalapril</a></li>
<li><a href="Enalaprilat.htm" tppabs="https://ptable.com/wiki/compounds/A/Enalaprilat" title="Enalaprilat">Enalaprilat</a></li>
<li><a href="Fosinopril.htm" tppabs="https://ptable.com/wiki/compounds/A/Fosinopril" title="Fosinopril">Fosinopril</a></li>
<li>Gemopatrilat</li>
<li>Imidapril</li>
<li><a href="Lisinopril.htm" tppabs="https://ptable.com/wiki/compounds/A/Lisinopril" title="Lisinopril">Lisinopril</a></li>
<li><a href="Moexipril.htm" tppabs="https://ptable.com/wiki/compounds/A/Moexipril" title="Moexipril">Moexipril</a></li>
<li>Omapatrilat</li>
<li><a href="Perindopril.htm" tppabs="https://ptable.com/wiki/compounds/A/Perindopril" title="Perindopril">Perindopril</a></li>
<li><a href="Quinapril.htm" tppabs="https://ptable.com/wiki/compounds/A/Quinapril" title="Quinapril">Quinapril</a></li>
<li>Quinaprilat</li>
<li><a href="Ramipril.htm" tppabs="https://ptable.com/wiki/compounds/A/Ramipril" title="Ramipril">Ramipril</a></li>
<li>Rentiapril</li>
<li><a href="Rescinnamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Rescinnamine" title="Rescinnamine">Rescinnamine</a></li>
<li><a href="Spirapril.htm" tppabs="https://ptable.com/wiki/compounds/A/Spirapril" title="Spirapril">Spirapril</a></li>
<li>Spiraprilat</li>
<li>Temocapril</li>
<li><a href="Trandolapril.htm" tppabs="https://ptable.com/wiki/compounds/A/Trandolapril" title="Trandolapril">Trandolapril</a></li>
<li>Zofenopril</li>
<li>Zofenoprilat</li></ul>

<ul><li><i>Renin inhibitors:</i> <a href="Aliskiren.htm" tppabs="https://ptable.com/wiki/compounds/A/Aliskiren" title="Aliskiren">Aliskiren</a></li>
<li><span class="new">Ciprokiren</span></li>
<li><span class="new">Ditekiren</span></li>
<li><span class="new">Enalkiren</span></li>
<li><span class="new">Imarikiren</span></li>
<li><a href="Pepstatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Pepstatin" title="Pepstatin">Pepstatin</a></li>
<li><a href="Remikiren.htm" tppabs="https://ptable.com/wiki/compounds/A/Remikiren" title="Remikiren">Remikiren</a></li>
<li><span class="new">Terlakiren</span></li>
<li><span class="new">Zankiren</span></li></ul>

<ul><li><i>Propeptides:</i> Angiotensinogen</li>
<li>Angiotensin I</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><i>Combinations:</i></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Valsartan/hydrochlorothiazide</li>
<li>Valsartan/hydrochlorothiazide/amlodipine</li>
<li>Amlodipine/valsartan</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Signaling peptide/protein receptor modulators</i></dd></dl>
</div></td></tr></tbody></table></div><span>
</span>










<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-02" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Losartan&oldid=970755871  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Losartan&oldid=970755871'" tppabs="https://en.wikipedia.org/wiki/?title=Losartan&oldid=970755871">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>